CancerNetwork Members: Login | Register
 
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
PATIENTS
NURSES
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

Oncology NEWS International. Vol. 16 No. 11
Pages: 1  2  3  4  
Next
 

Dr. Norton hopes to weed 'molecular' tumor garden

By
Jamie Talan, reporter at large | November 1, 2007

NEW YORK—Larry Norton, MD, is a gardener in the truest sense of the word. He is planting an idea (tumor self-metastasis) that could ultimately grow into a new way to understand and treat cancer. For decades, Dr. Norton, of Memorial Sloan-Kettering Cancer Center, accepted that cancer is a disease of cell division not unlike an acorn giving rise to an oak tree. But these days, his garden is full of weeds, and that has sprouted the theory that each tumor may be a collection of individual seeds that grow wildly in a bed—a product of cell migration and not necessarily unstoppable division.

"Each weed bed is not particularly big or aggressive or fast-growing," Dr. Norton said, but together they can form a large aggressive tumor. "And each weed grows independently, throwing seeds to the wind that may, in turn, end up in the neighbor's garden."

If Dr. Norton is right—and scientists at Memorial and other cancer centers around the world are testing this idea—it could explain why the current crop of medicines that target cell invasion are not curing cancer.

"I have spent most of my career developing therapies that target cell division," said Dr. Norton, who graduated medical school in 1972, a year after Nixon declared war on cancer. "But now I have come to believe that we may have been wrong in focusing our energies on cell division. It may not be a defining feature after all."

The Gompertzian curve

Dr. Norton is saying that biology and genetics may not be enough to explain the complex nature of tumorigenesis. In fact, he's using an old and powerful mathematical formula—the Gompertzian curve—that has been used to explain many events in nature.

He first used this model on the biological level to develop the idea of dose-dense therapy and now is using it on the molecular level to explain how tumors grow and metastasize.

In 1825, Benjamin Gompertz hypothesized that biological growth (such as population growth) follows a characteristic curve of rapid growth followed by slower growth, to an ultimate plateau. Applied to cancer, the Gompertzian curve suggests that malignant cells increase rapidly in number, then settle into slow growth up to a plateau. In this model, tumors can regress with treatment, but then, unless every single cancer cell is destroyed, the cancer cells naturally start increasing again in the rapid cycle mode.

Pages: 1  2  3  4  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





Jamie Talan is a science-writer-in-residence at The Feinstein Institute for Medical Research.


 
TOPIC INDEX

  • Bladder Cancer
  • Bone Metastases
  • Breast Cancer
  • CML
  • Colorectal Cancer
  • End-of-Life
  • GIST
  • Genetics Genomics
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Integrative Oncology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Nausea & Vomiting
  • Palliative Care
  • Pancreatic Cancer
  • Practice Management
  • Practice & Policy
  • Prostate Cancer
  • RCC
  • Skin Cancer
  • Triple-Negative Breast
  • Testicular Cancer


More Topics 

 
PUBLICATIONS
ONCOLOGY Journal ONCOLOGY Nurse Edition Journal Cancer Management: A Multidisciplinary Approach

ONCOLOGY:
Perspectives on Best Practices

ONCOLOGY:
Nurse Edition

CANCER
MANAGEMENT
:
A Multidisciplinary
Approach


 
IMAGE IQ

Other than surgical interventions, which medication might be most appropriate for this patient?

A 68-year-old woman presented with a mass on the scalp. An incisional biopsy of the scalp mass and an excisional biopsy of the lymph node both revealed basal cell carcinoma.

 

More Image IQs:

 

 
FROM PHYSICIANS PRACTICE
'What They Should Really Teach in Medical School'
Julie Schopps, MD , February 6, 2012
The North Carolina-based pediatrician weighs in on why she thinks the real learning doesn't take place until students are out of the classroom.
Improve EHR Systems by Rethinking Medical Billing
Daniel Essin, MA, MD, February 6, 2012
Separating billing-related data from other clinical documentation and transmitting it to a billing system is not difficult …no matter how the charting is done.
Keeping Your Medical Practice’s Accounts Receivable on Track
P.J. Cloud-Moulds, February 4, 2012
Here are the minimum reports you should be running to keep an eye on your practices A/R.
Healthcare Providers Play Crucial Role in Helping Victims of Abuse
Stephen Hanson, PA-C , February 3, 2012
I would urge each and every one of you to be familiar with the warning signs of abuse, and the resources available to you all as healthcare providers.
Protecting Your Medical Practice's Data
Marisa Torrieri, February 3, 2012
Here's the scoop on how to implement a good data-backup plan at your office.
 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Management of Brain Metastases: Neurosurgical Considerations
  • Head and Neck Tumors
  • Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
  • A 28-Year-Old Woman Presents With a Long-Standing History of Intermittently Painful “Bumps” on Both Her Shoulders and Upper Back
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Ending the Shortage of Generic Oncology Drugs
  • Processed and Red Meat Consumption Linked to Slight Increase in Risk of Pancreatic Cancer
  • Younger Breast Cancer Patients Have More Adverse Quality of Life Issues
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Could Aspirin Be a Viable Adjuvant Treatment for Cancer?
  • AL Amyloidosis: Who, What, When, Why, and Where
  • The Maze of PARP Inhibitors in Ovarian Cancer
  • The Circuitous Path of PARP Inhibitor Development in Epithelial Ovarian Cancer
  • Podcast: Dr. David Ahlquist on Advances in Colorectal Cancer Screening
  • Lung Cancer Screening: A New Era
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?
  • Evolving Therapeutic Paradigms for Advanced Prostate Cancer
Click here to subscribe to our newsletter
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs



CancerNetwork on Facebook

 

CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy